Helping Individuals Who Struggle With Depression
The Ketamine Service at McLean Hospital offers specialized treatment for adults struggling with depression, especially major depressive disorder and bipolar disorder.
Our data-driven, evidence-based service applies cutting-edge research to clinical practice. We create personalized treatments based on thorough, scientific evaluation of each patient.
Although it has been used for years as an anesthetic, ketamine has been shown to be a highly effective treatment for many individuals who struggle with severe depression. In addition, those who are experiencing symptoms that are threatening their health or safety may be good candidates for ketamine, which can often work more quickly than other treatments.
Our dedicated treatment team includes psychiatrists, anesthesiologists, and nursing staff who have both medical and psychiatric training. Staff are uniquely equipped to assist our patient population and ensure that treatments are administered in the safest manner possible.
We offer two types of ketamine therapy: IV ketamine infusion and intranasal esketamine administration. Our services are available as outpatient treatments or as a component of inpatient care.
Ketamine infusions are delivered via intravenous (IV) procedure over 40 minutes. Patients remain awake during the treatment. Many individuals opt to read, listen to music, or just relax. Patients are monitored before, during, and after the treatment according to evolving standards of best and safe practice.
Esketamine (Spravato) is FDA approved for the treatment of patients who struggle with major depressive disorder. People who receive esketamine are also on other antidepressant medications. Esketamine is self-administered intranasally under the supervision of a nurse. Patients are also monitored before, during, and after this treatment. Our procedures are in line with the FDA-mandated REMS reporting system.
McLean’s Ketamine Service is located within the ECT/TMS suite in the de Marneffe Building on McLean’s Belmont campus.
Ketamine and esketamine have been shown to be effective interventions for severe depression, with or without anxiety, particularly for individuals who have struggled with standard therapies. In recent years, research efforts and reports from ketamine clinics have demonstrated success in using these drugs to quickly and effectively address severe depression.
At McLean, ketamine and esketamine are used to help depressed individuals who have not responded to at least two courses of medications most often prescribed for depression. They can also help individuals who are experiencing acute suicidal thoughts or behaviors and who would benefit from a fast-acting intervention. It is important to note that ketamine therapies should never be considered as a replacement for psychiatric admission for patients who may be a danger to themselves or others.
The Ketamine Service works alongside McLean’s Electroconvulsive Therapy (ECT) and Transcranial Magnetic Stimulation (TMS) Services. Patient treatment plans are customized to meet the needs of the individuals and may include the options for any of these interventions.
Patient consultations determine whether ketamine infusions, intranasal esketamine, electroconvulsive therapy (ECT), or transcranial magnetic stimulation (TMS) is the appropriate course of treatment for the patient’s psychiatric symptoms, diagnoses, and treatment goals.
If a thorough evaluation indicates that ketamine or esketamine is the right approach, an appointment is made for a medical clearance before the first treatment.
Depending on the patient’s treatment goals, people coming to the Ketamine Service for IV ketamine may receive a single infusion of ketamine, engage in a course of 3-4 infusions (a so-called “ketamine challenge”), or take part in a series of 8 infusions (“acute phase”), with subsequent treatment tapered according to individual need.
Esketamine treatments follow an FDA-approved algorithm with twice weekly administrations during the acute phase, followed by a second phase with weekly treatments and finally transition to a maintenance phase of treatment (generally every 1-3 weeks).
Admission & Cost
McLean’s Ketamine Service provides treatment to adults with depression, with or without accompanying anxiety or other symptoms, especially patients with major depressive disorder or bipolar disorder. The program is ideal for individuals who have previously struggled with standard therapies or who are at risk to themselves or others and require urgent intervention.
For more information about our program or to make a referral, please contact our administrative staff:
Referring clinicians should fill out the Ketamine Service Referral Form so that we may determine whether the program is good fit for the individual and gather the appropriate patient information.
Generally, consultations are covered by insurance. Coverage of IV ketamine and intranasal esketamine varies by insurance company. Please be sure to check with your insurance provider to learn more about what your plan may cover.
For patients who pay for the treatments out of pocket and seek reimbursement for ketamine treatment from their insurance providers, we can assist you by providing requested documentation.
McLean Hospital accepts Medicare, Massachusetts Medicaid, and many private insurance and managed care plans. More information on insurance providers accepted by McLean Hospital may be found on the Mass General Brigham website. You may also find it beneficial to review McLean’s patient billing and financial assistance information.